Becton, Dickinson and Company $BDX Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 85,346 shares of the medical instruments supplier’s stock after selling 14,725 shares during the quarter. Corient Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $16,585,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Auto Owners Insurance Co increased its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after acquiring an additional 40,528,680 shares during the period. Union Savings Bank purchased a new stake in Becton, Dickinson and Company in the 4th quarter valued at $76,000. Hsbc Holdings PLC boosted its stake in Becton, Dickinson and Company by 53.7% during the 4th quarter. Hsbc Holdings PLC now owns 940,908 shares of the medical instruments supplier’s stock worth $183,161,000 after purchasing an additional 328,717 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth $112,000. Finally, Bayban purchased a new position in Becton, Dickinson and Company during the 4th quarter worth $36,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BDX shares. The Goldman Sachs Group reduced their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Bank of America decreased their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Argus lowered their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Finally, Evercore upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $181.00.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $144.39 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average is $148.40 and its two-hundred day moving average is $171.47. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market capitalization of $39.79 billion, a PE ratio of 36.55, a P/E/G ratio of 9.96 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the prior year, the business posted $3.35 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the transaction, the executive vice president owned 14,272 shares in the company, valued at $2,161,922.56. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,013 shares of company stock worth $593,434 over the last 90 days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.